{"summary":"Extensive oncology biotechnology, pharmaceutical, and diagnostic experience.  Strong business development and program\/project management skills in clinical research, medical training and education, and scientific\/medical communications.  ","lastName":"Burke","objectUrn":"urn:li:member:25262111","geoRegion":"Indialantic, Florida, United States","fullName":"Emily Burke","firstName":"Emily","currentPositions":[{"companyName":"Natera","description":"\u2022 Responsible for building key partnerships with academic institutions and network groups in guideline-enabling oncology clinical trials that drive Signatera reimbursement and clinical adoption in the US and Canada","title":"Director, US Oncology Market Business Development","companyUrnResolutionResult":{"website":"http:\/\/www.natera.com","formattedRevenue":{"unit":"MILLION","amount":210.9,"currencyCode":"USD"},"industry":"Biotechnology Research","employeeCountRange":"1001-5000","headquarters":{"geographicArea":"Texas","country":"United States","city":"Austin","postalCode":"78753","line1":"13011A McCallen Pass"},"revenue":{"amount":"210939000","currencyCode":"USD"},"flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/natera\/"},"companyUrn":"urn:li:fs_salesCompany:1051903","tenureAtCompany":{"numYears":1},"startedOn":{"month":6,"year":2023}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAGBeB8BfQ1OhvSw9Ey9xX0iwOMm0XAfzTc,NAME_SEARCH,r-lB)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1611100857127?e=1723075200&v=beta&t=T1778DmHa-T3xQn5u7kZkm3fDeL8AV5Ka1M1r6J-eqI","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1611100857127?e=1723075200&v=beta&t=cUTWg-vKaqftImoxSdSXUBQ2g-HMZRD1gFEo9m42Qt8","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1611100857127?e=1723075200&v=beta&t=XXyhAlpgKtIBWVA5Iz2WzfY4dV5uwIZ_9xacUzCuIa4","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1611100857128?e=1723075200&v=beta&t=0yfMGTGi7Z0qBuacW_c05nbFsg-nEWvPgw9AW1nmVlI","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQES5NPuI-9X7A\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2003},"degree":"MS","eduId":31150002,"schoolUrn":"urn:li:fs_salesSchool:15133595","school":"urn:li:fs_salesSchool:15133595","fieldsOfStudy":["Genetic Counseling"],"schoolName":"The University of Texas M.D.  Anderson Cancer Center","startedOn":{"year":2001}},{"endedOn":{"year":2000},"degree":"BS","eduId":21836444,"schoolUrn":"urn:li:fs_salesSchool:6382","school":"urn:li:fs_salesSchool:6382","fieldsOfStudy":["Microbiology"],"schoolName":"Ohio University","startedOn":{"year":1996}}],"skills":[{"numOfEndorsement":0,"name":"Precision Medicine"},{"numOfEndorsement":0,"name":"Cross-functional Team Leadership"},{"numOfEndorsement":0,"name":"Competitive Landscape"},{"numOfEndorsement":0,"name":"Development Strategy"},{"numOfEndorsement":1,"name":"Publication Strategy"},{"numOfEndorsement":1,"name":"Communications Planning"},{"numOfEndorsement":1,"name":"Scientific Communications"},{"numOfEndorsement":2,"name":"Clinical Trials"},{"numOfEndorsement":1,"name":"Medical Communications"},{"numOfEndorsement":28,"name":"Oncology"},{"numOfEndorsement":17,"name":"Biotechnology"},{"numOfEndorsement":14,"name":"Genomics"},{"numOfEndorsement":15,"name":"Life Sciences"},{"numOfEndorsement":8,"name":"Genetics"},{"numOfEndorsement":7,"name":"Cancer"},{"numOfEndorsement":7,"name":"Product Launch"},{"numOfEndorsement":7,"name":"Healthcare"},{"numOfEndorsement":5,"name":"Lifesciences"},{"numOfEndorsement":7,"name":"Clinical Research"},{"numOfEndorsement":3,"name":"Assay Development"},{"numOfEndorsement":2,"name":"Medical Education"},{"numOfEndorsement":1,"name":"Molecular Biology"},{"numOfEndorsement":7,"name":"Molecular Diagnostics"},{"numOfEndorsement":8,"name":"Medical Affairs"},{"numOfEndorsement":5,"name":"Personalized Medicine"},{"numOfEndorsement":3,"name":"Medical Diagnostics"},{"numOfEndorsement":2,"name":"Diagnostics"},{"numOfEndorsement":2,"name":"Cancer Genomics"},{"numOfEndorsement":0,"name":"Breast Cancer"},{"numOfEndorsement":0,"name":"Genetic Counseling"},{"numOfEndorsement":0,"name":"Genetic Testing"},{"numOfEndorsement":0,"name":"Medical Genetics"}],"numOfConnections":1395,"patents":[],"headline":"Director, Oncology Market Business Development","courses":[],"certifications":[],"memberBadges":{"premium":true,"openLink":true,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/emilyburke9","organizations":[],"location":"Indialantic, Florida, United States","publications":[],"positions":null,"posts":[{"createdAt":1716923040000,"insightId":"4031bb6e-b91e-4097-a6a7-2c8cf80aaf94","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":6},{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7201297316824129536","threadUrn":"urn:li:activity:7201297316824129536","reactionsCount":7,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7201297316262072320","message":{"attributes":[],"text":"Tomorrow, join Natera's webinar exploring the value of ctDNA in gynecologic oncology.  Exciting area of clinical development and utility!"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQExO12Ou-qG2A\/image-shrink_1280\/0\/1716915315269?e=1717977600&v=beta&t=k9bmGcc5A81lZRqV9RkPFmfiMFlvhrfy9J2IadbSpdQ","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQExO12Ou-qG2A\/image-shrink_1280\/0\/1716915315269?e=1717977600&v=beta&t=k9bmGcc5A81lZRqV9RkPFmfiMFlvhrfy9J2IadbSpdQ"}]},"description":"Latest data on ctDNA as a patient selection and early efficacy marker for gynecologic cancers","resolvedUrl":"https:\/\/ow.ly\/RFhV50RYoCa","title":"Upcoming Webinar"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7201264774104461312","message":{"attributes":[{"start":59,"length":6,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:ctdna"}}},{"start":119,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:gynecologic"}}},{"start":891,"length":25,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/ow.ly\/RFhV50RYoCa"}}}],"text":"[WEBINAR] Join us tomorrow for our webinar: Latest data on #ctDNA as a patient selection and early efficacy marker for #gynecologic cancers. \n\nCirculating tumor DNA (ctDNA), as measured by the Signatera assay, has emerged as a highly sensitive biomarker to identify patient populations who are at high risk of relapse and may benefit from additional treatment.\n\nSignatera\u2122 is now covered by Medicare for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and surveillance settings, expanding access to testing.\n\nOur expert speakers will discuss the latest data from recent publications and SGO 2024 supporting the use of ctDNA in gynecologic cancer clinical practice and trials.\n\nThis will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space.\n\nhttps:\/\/ow.ly\/RFhV50RYoCa"},"entityUrn":"urn:li:share:7201264774104461312"},"entityUrn":"urn:li:share:7201297316262072320"}}},{"createdAt":1716472560000,"insightId":"c7c6845d-c352-47e7-8a52-fba212e05b88","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":17},{"type":"PRAISE","count":3},{"type":"INTEREST","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7199407834097147905","threadUrn":"urn:li:activity:7199407834097147905","reactionsCount":21,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7199407832323010560","message":{"attributes":[],"text":"Great new data coming out next week at ASCO.  Looking forward to seeing all in Chicago!"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQHd8F9Are-G-Q\/image-shrink_1280\/0\/1716468614557?e=1717977600&v=beta&t=SByKLdc1LOp2GBpF6x8hTKZWHIauuPEsGI6T59MNGuw","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E10AQHd8F9Are-G-Q\/image-shrink_1280\/0\/1716468614557?e=1717977600&v=beta&t=SByKLdc1LOp2GBpF6x8hTKZWHIauuPEsGI6T59MNGuw"}]},"description":"AUSTIN, Texas\u2013(BUSINESS WIRE)\u2013 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 \u2013 June 4, 2024. The presentations feature data across a variety [\u2026]","resolvedUrl":"https:\/\/ow.ly\/cv0R50RSpGq","title":"Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7199391175382810625","message":{"attributes":[{"length":10,"start":375,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:signatera"}}},{"length":11,"start":533,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:1004174162"}}},{"length":6,"start":587,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1051903"}}},{"length":25,"start":966,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/ow.ly\/cv0R50RSpGq"}}},{"length":7,"start":993,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:natera"}}},{"length":7,"start":1001,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:asco24"}}},{"length":15,"start":1009,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerresearch"}}}],"text":"We are pleased to present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 \u2013 June 4, 2024.\n\nOur presentations feature data across a variety of indications, including breast cancer, colorectal cancer, lung cancer, melanoma, esophageal cancer, and urothelial cancer, with one oral presentation and 12 poster presentations on #Signatera, our personalized and tumor-informed molecular residual disease test, as well as one poster with data on Empower, our test for hereditary cancer.\n\nMinetta Liu, MD, chief medical officer of oncology at Natera, said, \u201cWe look forward to sharing new data across cancer types, reflecting Natera\u2019s deep clinical pipeline in MRD with results from randomized trials as well as real-world studies. This includes promising new findings from the CIRCULATE-Japan GALAXY study demonstrating the prognostic and predictive utility of Signatera and actionable biomarkers in colorectal cancer.\u201d\n\nhttps:\/\/ow.ly\/cv0R50RSpGq\n\n#Natera #ASCO24 #CancerResearch"},"entityUrn":"urn:li:share:7199391175382810625"},"entityUrn":"urn:li:share:7199407832323010560"}}},{"createdAt":1713001500000,"insightId":"d9811e0f-5ed8-4739-8a8d-bb218f362c0f","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":46},{"type":"PRAISE","count":6},{"type":"INTEREST","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7184849164466298880","threadUrn":"urn:li:activity:7184849164466298880","reactionsCount":54,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184849164004921344","message":{"attributes":[],"text":"Huge advancement in drug development - MRD approved as an endpoint in clinical trials.  What a difference this can make for patients!"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGKjiMJFFxpuw\/feedshare-shrink_2048_1536\/0\/1712950360603?e=1720051200&v=beta&t=cN58hM-pPEbswNiOuSfDj8-Mpa1grCUMnRhRdf-x6fM"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184634553158795266","message":{"attributes":[{"start":14,"length":3,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:4652"}}},{"start":227,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:multiplemyeloma"}}},{"start":245,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:mmsm"}}},{"start":251,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncology"}}},{"start":261,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/ehGzUhCr"}}}],"text":"BREAKING: The FDA's Oncologic Drugs Advisory Committee voted 12 to 0 that the totality of available data supports the use of minimal residual disease as an end point for accelerated approval of new treatments for patients with #MultipleMyeloma. #mmsm #oncology https:\/\/lnkd.in\/ehGzUhCr "},"entityUrn":"urn:li:share:7184634553158795266"},"entityUrn":"urn:li:share:7184849164004921344"}}},{"createdAt":1711995540000,"insightId":"8d5df09f-c540-494d-bf99-8501f68ae1b8","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":21},{"type":"PRAISE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7180629802926637059","threadUrn":"urn:li:activity:7180629802926637059","reactionsCount":23,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7180629802419134464","message":{"attributes":[{"start":198,"length":20,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:personalizedtherapy"}}}],"text":"Excited to partner with Alliance for this pivotal ground-breaking trial!   The MODERN trial will use ctDNA to guide IO therapy for patients with MIUC, with both escalation and de-escalation arms.   #personalizedtherapy"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D10AQGxKaszNNIFOA\/image-shrink_1280\/0\/1711981517797?e=1717977600&v=beta&t=M-Vh-fDLosML8mYHU8jniKlTwJrAUYOGtNYSNVp_Pw4","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D10AQGxKaszNNIFOA\/image-shrink_1280\/0\/1711981517797?e=1717977600&v=beta&t=M-Vh-fDLosML8mYHU8jniKlTwJrAUYOGtNYSNVp_Pw4"}]},"description":"First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms Approximately 1,000 patients will be enrolled at more than 300 sites AUSTIN, Texas\u2013(BUSINESS WIRE)\u2013 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical [\u2026]","resolvedUrl":"https:\/\/www.natera.com\/company\/news\/natera-and-alliance-for-clinical-trials-in-oncology-announce-activation-of-alliance-a032103-modern-a-randomized-phase-ii-iii-adjuvant-trial-in-urothelial-cancer\/","title":"Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II\/III Adjuvant Trial in Urothelial Cancer"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7180570926621597696","message":{"attributes":[{"length":40,"start":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:8279107"}}},{"length":25,"start":135,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:6854241"}}},{"length":6,"start":381,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1051903"}}},{"length":14,"start":717,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:26764653"}}},{"length":25,"start":1210,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/ow.ly\/i7CX50R5I9F"}}}],"text":"Together with the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, we're pleased to announce the launch of Alliance A032103 (MODERN), a randomized, phase II\/III, biomarker-integrated trial.\n\nAlliance A032103 (MODERN) will utilize Signatera, Natera\u2019s personalized and tumor-informed molecular residual disease (MRD) test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer (MIUC) after radical cystectomy.\n\n\u201cThe MODERN trial represents a step towards precision medicine in bladder cancer treatment,\u201d said Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute. \u201cBy using Signatera to measure residual cancer after surgery, the Alliance A032103 (MODERN) trial may ultimately help to tailor the use of immunotherapy after surgery and optimize the care of individual patients.\u201d\n\nRead more below. https:\/\/ow.ly\/i7CX50R5I9F"},"entityUrn":"urn:li:share:7180570926621597696"},"entityUrn":"urn:li:share:7180629802419134464"}}},{"createdAt":1710867120000,"insightId":"6d379464-df15-47cf-9d9d-335ede05fb87","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:job:3860519370"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":16}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7175896861440913410","threadUrn":"urn:li:activity:7175896861440913410","reactionsCount":16,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7175896860857921537","message":{"attributes":[],"text":"New opportunity- if you have a passion for health care innovation and a strong background in AI, especially within oncology, check out this job at Natera: Director, Clinical Artificial Intelligence"},"entityUrn":"urn:li:share:7175896860857921537"}}},{"createdAt":1715554740000,"insightId":"3ac42ef3-90f1-4465-b144-d18e4d734446","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7195193069095333888,7195558125049913344)","threadUrn":"urn:li:ugcPost:7195193069095333888","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7195193069095333888"}}},{"createdAt":1712598720000,"insightId":"3410b2cc-5f7d-4d9d-bfa5-84ec9f4e293f","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7183156835149864960,7183159771171016704)","threadUrn":"urn:li:ugcPost:7183156835149864960","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"You're such a great marketer!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7183156835149864960"}}},{"createdAt":1711034280000,"insightId":"885b0711-102d-4577-82f5-9ce96721207e","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7176583598404251648,7176598097483993090)","threadUrn":"urn:li:activity:7176583598404251648","reactionsCount":4,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"I'm a \"hi, good morning.  Have a quick question about XYZ.\"   I like context"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7176583598404251648"}}}]}